Sapien Dialogue Covid19 - Our new weekly webinar series

We have launched our new weekly webinar series - Sapien Dialogue Covid19 that focuses on the most crucial topics surrounding the Covid19 impact and how the industries, startups and stakeholders should survive this extremely challenging phase across several sectors.

Sapien Dialogue Covid19 – Week 5 (6th May 2020)

Topic: Auto & Auto Ancillaries, Investment Outlook Post Covid

Panel Guest:
Mr. Nitai Utkarsh, Lead – Investment Strategy & Chairman’s Family OfficeHero MotoCorp Ltd
Moderator – Deepa Balasubramanian, CEO, The Sedibus

Sapien Dialogue Covid19 – Week 4 (29th April 2020)

Topic: FMCG During Covid19 – Navigating Through the Crisis

Panel Guest:
Mr. Ashwin A, City head Hyderabad & Chennai, Licious
Moderator – Deepa Balasubramanian, CEO, The Sedibus

Sapien Dialogue Covid19 – Week 3 (22nd April 2020)

Topic: Agriculture Post Covid19 – Revival, Security and Safety

Panel Members:
Mr. Ramesh Deshpande Former Senior Staff, Reserve Bank of India and the World Bank, Washington DC.Member, The 1818 Society, World Bank Group Alumni
Mr. Ram Janakiram Consultant, The World Bank
Mr. Amalor Pavanathan ormer DMD, NABARD
Moderator – Bhaskar Chalasani, Chairman, Dhakshhin Agropolis Ltd

Sapien Dialogue Covid19 – Week 2 (15th April 2020)

Topic: CoroFlu Vaccine, Bharat Biotech’s Mission to Fight Covid19

Panel Members:
Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech International Limited
Dr. Raches Ella, Head Business Development & Advocacy, Bharat Biotech International Limited

Focus areas of discussion – Vaccine for Covid19 

Few Questions raised and discussed:
  • What are the odds of CoroFlu making it to the top of the line, we have been hearing a lot about M2SR, a self-limiting version of the influenza virus that induces an immune response against the flu? It is said that you are utilizing gene sequences from SARS Cov 2, can you tell us a little more about the vaccine in totality
  • Bharat Biotech has partnered with the University of Wisconsin Madison and US-based company FluGen to develop the Coro-Flu vaccine. How, when and Why this particular collaboration with FluGen?
  • It has been said that Under the collaboration agreement, FluGen will transfer its existing manufacturing processes to Bharat Biotech, and this will enable the company to scale up production and produce the vaccine for clinical trials. What is the timeline that we are looking at? Including trials, pre-clinical trials, approvals and the eventual mftg and distribution.
  • How do you see the pharma industry changing in the days to come, with demand-supply modalities? Some say that the recent approval to export Hydroxychloroquine to the United States will change the fate of some brands, while others speculate constant evolution in the way companies researched and produced drugs for these kinds of viruses. What is your take on this?
  • Indian Pharma is racing against time to produce a viable vaccine for Covid19, we are talking about brands like Serum Institute, Zydus Cadilla running along with Bharat Biotech. Has covid19 changed the way Indian Pharma companies work and operate?
  • Consider CoroFlu Vaccine getting ready before everyone else, what are the plans of Bharat Biotech so as to be able to reach out widely and effectively? You did hint at the production of 300 million doses per year.
  • Over time, the veracity of the virus may come down as it’s slippery, mutates fast, and every mutation makes it weaker. If the vaccine comes out after a year or so, will it be effective, as in will people require it at all, will the Covid19 end up becoming the common flu-like thing in the future? What are the possibilities?

Sapien Dialogue Covid19 – Week 1 (7th April 2020)

Topic: How Healthcare, Pharma and Technology can come together to fight Covid19

Panel Members:
Dr. Sudhir Kumar MD, DM, Apollo Hospitals, Hyderabad
S.V. Krishna Prasad, Founder & CEO, Cito Healthcare
Akul Penugonda, Principal, Acceleprise & Advisor, The Sedibus

Focus areas of discussion – Healthcare, Pharma and Emerging to Deep Tech 

Few Questions raised and discussed:
  • Understanding the gravity of the situation on the ground – what’s happening in the war zones in the corona wards of Hospitals in Hyderabad and elsewhere?
  • What was the situation like at the time of conditions like swine flu and chikungunya and how is it now? Do we see any hope with this extremely contagious disease?
  • China has contained the situation in the later stages by using technology in the form of facial recognition, geo tagging and surveillance mechanisms on the covid positives. Do we think something similar should be emulated by other countries in the world, and if so, what are the opportunities and limitations here?
  • There have been talks about risks doctors are constantly facing with exposure to the isolation wards, can startups innovate furthermore in the healthcare sector to empower the medical professional better. There are several PPE manufacturers who are suddenly surfacing but is that enough?
  • Several drug companies across the world are now on a war footing to develop vaccines for covid, such as CanSino Biological, a company that developed Ebola Vaccine in 2017. As per the recent reports they have 2 candidates entering human trials and 60 in pre clinical stage. Then we have names like Curevac, INOVIO, not to forget Indian entities like Bharat Biotech, Zydus Cadila and Serum Institute working on vaccines, what will be results of the efforts and how far along to get into successful trials and eventual manufacturing and distribution?
  • What startups into deep tech, biotech and health tech should focus on in these trying times to stay afloat, some of them are already struggling to reduce their burn rate and maintain runway for the coming few months, maybe two years, but really, what should they work on in order to survive this phase?
  • Now that we are coping with lockdown and a new way of life, some of the startups will definitely be on low morale basis their mental state of mind. Any suggestions for all of us to cope with this slowdown mentally and keep the focus going?
  • What are the other possibilities that we foresee in the coming days in the pharma sector, and would be the good opportunity to work on tech innovation to join the forces as the startups work on R&D, innovation for laboratory diagnostics and medical research?
  • What are the thoughts on the role of govts and private stakeholders to empower tech startups at this point? While cash is the king, will schemes and innovative competitions make any difference? What else should be done?